|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5462990A
(en)
|
1990-10-15 |
1995-10-31 |
Board Of Regents, The University Of Texas System |
Multifunctional organic polymers
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
AU687727B2
(en)
|
1992-10-28 |
1998-03-05 |
Genentech Inc. |
Vascular endothelial cell growth factor antagonists
|
|
WO1994010187A1
(en)
|
1992-10-30 |
1994-05-11 |
Hsc Research And Development Limited Partnership |
COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
|
|
US5830847A
(en)
*
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
MX9701946A
(es)
|
1997-03-14 |
1998-04-30 |
Arturo Jimenez Bayardo |
Solucion oftalmica transportadora.
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
PT971959E
(pt)
|
1997-04-07 |
2006-05-31 |
Genentech Inc |
Anticorpos humanizados e metodos para formar anticorpos humanizados
|
|
KR100816621B1
(ko)
|
1997-04-07 |
2008-03-24 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
|
AU784231B2
(en)
|
2000-06-23 |
2006-02-23 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
|
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
|
DK1638941T3
(da)
|
2003-05-22 |
2010-10-11 |
Abbott Lab |
Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
|
|
UA101945C2
(uk)
|
2003-05-30 |
2013-05-27 |
Дженентек, Инк. |
Лікування злоякісного новоутворення за допомогою бевацизумабу
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20090286271A1
(en)
|
2006-05-31 |
2009-11-19 |
Karumanchi Ananth S |
Methods of Diagnosing and Treating Complications of Pregnancy
|
|
WO2007143023A1
(en)
|
2006-05-31 |
2007-12-13 |
Beth Israel Deaconess Medical Center |
Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
|
|
CN111518218A
(zh)
|
2006-11-02 |
2020-08-11 |
阿塞勒隆制药公司 |
Alk1受体和配体拮抗剂及其用途
|
|
MX2009012934A
(es)
|
2007-06-01 |
2009-12-15 |
Wyeth Corp |
Metodos y composiciones para modular la actividad de bmp-10.
|
|
US20100210713A1
(en)
*
|
2009-01-16 |
2010-08-19 |
The General Hospital Corporation |
Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
|
|
EP2209003A1
(en)
*
|
2009-01-16 |
2010-07-21 |
F. Hoffmann-Roche AG |
Means and methods for differentiating between fibrosis and cirrhosis
|
|
JP5755635B2
(ja)
*
|
2009-03-30 |
2015-07-29 |
アクセルロン ファーマ， インコーポレイテッド |
Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
|
|
WO2010128158A1
(en)
|
2009-05-08 |
2010-11-11 |
Novartis Ag |
Diagnostic biomarkers for fibrotic disorders
|
|
WO2011088047A1
(en)
|
2010-01-12 |
2011-07-21 |
Beth Israel Deaconess Medical Center |
Soluble endoglin and uses thereof
|
|
JP6250533B2
(ja)
*
|
2011-04-20 |
2017-12-20 |
アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． |
エンドグリンポリペプチドおよびその使用
|
|
EP2739645B1
(en)
*
|
2011-08-01 |
2018-12-19 |
Tufts Medical Center, Inc. |
Endoglin-specific antibody for use in a method of treating heart failure and related conditions
|
|
US10214590B2
(en)
|
2013-09-20 |
2019-02-26 |
Tufts Medical Center, Inc. |
Inhibitors of endoglin activity for the treatment of fibrosis
|
|
EP3851118A1
(en)
|
2013-10-25 |
2021-07-21 |
Acceleron Pharma Inc. |
Endoglin peptides to treat fibrotic diseases
|
|
CA2966905A1
(en)
*
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|